Aprea Therapeutics Secures $34M in Private Placement Financing: A Major Step Forward in Oncology Research. In a significant development in the field of precision oncology, Aprea Therapeutics, Inc. (NASDAQ: APRE) announced a private placement financing of up to $34 million. The financing is set to close around March 13, 2024, subject to customary closing conditions. The proceeds will be used to fund a...
$Aprea Therapeutics(APRE.US)$Item 8.01Other Events. On October 16, 2023, Aprea Therapeutics, Inc. issued a press release announcing initial clinical data on ATRi, ATRN-119, and pre-clinical data on WEE1i, ATRN-1051, presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, supporting highly differentiated synthetic lethality portfolio. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
$Aprea Therapeutics(APRE.US)$ BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16 – 21, 2021. Details for the ESMO 2021 mini oral presentation are as follows: Title: Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies. Speaker: Haeseong Park, Washington University in St. Louis Presentation #: 516MO Session: Mini oral session – Developmental therapeutics Date and Time: Monday, September 20, 2021; 17:35 – 17:40 CEST (11:35 – 11:40am EDT) GlobeNewswire, Inc. 2021
Aprea Therapeutics股票讨论区
$34M Private Placement & FDA Clearance Secured By Therapeutics Company For Novel Cancer Treatment
In a significant development in the field of precision oncology, Aprea Therapeutics, Inc. (NASDAQ: APRE) announced a private placement financing of up to $34 million. The financing is set to close around March 13, 2024, subject to customary closing conditions. The proceeds will be used to fund a...
On October 16, 2023, Aprea Therapeutics, Inc. issued a press release announcing initial clinical data on ATRi, ATRN-119, and pre-clinical data on WEE1i, ATRN-1051, presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, supporting highly differentiated synthetic lethality portfolio. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Phase I/II study of eprenetapopt (APR-246)
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September
16 – 21, 2021.
Details for the ESMO 2021 mini oral presentation are as follows:
Title: Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
Speaker: Haeseong Park, Washington University in St. Louis Presentation #: 516MO
Session: Mini oral session – Developmental therapeutics
Date and Time: Monday, September 20, 2021; 17:35 – 17:40 CEST (11:35 – 11:40am EDT)
GlobeNewswire, Inc. 2021
https://www.moomoo.com/en-us/news/post/4769119/aprea-therapeutics-on-wednesday-received-fda-orphan-drug-designation-for-eprenetapopt-for-treatment-of-acute-myeloid-leukemia?src=2&report_type=stock&report_id=8974031&from=3&skin=1&utm_medium=futu_niuniu_share&utm_content=web_share&utm_campaign=news&utm_term=8974031&data_ticket=null
暂无评论